What is Zacks Research’s Forecast for CRL FY2027 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at Zacks Research issued their FY2027 earnings estimates for shares of Charles River Laboratories International in a note issued to investors on Wednesday, March 12th. Zacks Research analyst R. Department anticipates that the medical research company will earn $11.39 per share for the year. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share.

Other analysts have also issued reports about the stock. Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Barclays cut their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 18th. Finally, UBS Group reissued a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Trading Up 2.6 %

Shares of NYSE:CRL opened at $171.27 on Friday. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $274.77. The firm has a market cap of $8.76 billion, a P/E ratio of 1,141.78, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a 50 day moving average of $167.74 and a 200-day moving average of $184.59. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.46 EPS.

Insider Buying and Selling at Charles River Laboratories International

In related news, CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth $3,583,000. Jefferies Financial Group Inc. increased its stake in shares of Charles River Laboratories International by 226.7% during the 4th quarter. Jefferies Financial Group Inc. now owns 17,802 shares of the medical research company’s stock worth $3,286,000 after purchasing an additional 12,353 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of Charles River Laboratories International by 0.6% during the 4th quarter. Mackenzie Financial Corp now owns 977,073 shares of the medical research company’s stock worth $180,368,000 after purchasing an additional 5,805 shares during the last quarter. Forum Financial Management LP increased its stake in shares of Charles River Laboratories International by 30.3% during the 4th quarter. Forum Financial Management LP now owns 1,565 shares of the medical research company’s stock worth $289,000 after purchasing an additional 364 shares during the last quarter. Finally, Montchanin Asset Management LLC acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth $258,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).